Back to Search
Start Over
Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials
- Source :
- Frontiers in Oncology, Frontiers in Oncology, Vol 10 (2020)
- Publication Year :
- 2020
-
Abstract
- We reviewed all fully published clinical trials assessing anti-angiogenic agents in sarcoma patients (last issue, January 13, 2020). Anti-angiogenic macromolecules (e.g., bevacizumab or ombrabulin) provide disappointing results. Many multikinase inhibitors have been assessed with non-randomized phase II trials with limited samples and without stratification according to histological subtypes, therefore interpretation of such trials is very challenging. On the contrary, pazopanib, regorafenib, and sorafenib have been assessed using double-blind placebo-controlled randomized phase II or phase III trials. Compared to placebo, sorafenib demonstrates activity in desmoid-type fibromatosis patients. Based on results of phase 3 trial, pazopanib had obtained approval for treatment of pretreated non-adipocytic soft tissue sarcoma. Regorafenib is currently assessed in several clinical settings and provides significant improvement of progression-free survival in pre-treated non-adipocytic soft tissue sarcoma and in advanced pretreated osteosarcoma. Multikinase inhibitors are a breakthrough in sarcoma management. Many trials are ongoing. Nevertheless, predictive factors are still missing.
- Subjects :
- 0301 basic medicine
Sorafenib
Oncology
Cancer Research
medicine.medical_specialty
sarcoma
Bevacizumab
Ombrabulin
Review
lcsh:RC254-282
Pazopanib
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Regorafenib
medicine
business.industry
non-adipocytic soft tissue sarcoma
Soft tissue sarcoma
clinical trial
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Clinical trial
030104 developmental biology
Choi criteria
chemistry
030220 oncology & carcinogenesis
Sarcoma
business
multikinase inhibitor
medicine.drug
Subjects
Details
- ISSN :
- 2234943X
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Frontiers in oncology
- Accession number :
- edsair.doi.dedup.....2716b37b09e6f700a2f83f73bc3ddbb2